Mardia Formulation (India) Private Limited
About Mardia Formulation (India) Private Limited
Data last updated:
Mardia Formulation (India) Private Limited is a private limited company based in Palghar, Maharashtra, India. It operates in the chemical products segment of the chemicals sector. It was incorporated on 14 July 1999 and has been in existence for over 27 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH1999PTC120797. Its GSTIN is 27AABCM9536D1ZG (Maharashtra).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹4.01 Lakh. It is led by directors including Gayan Prakash Mardia and Anand Mardia.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Bl. No. 207 Renuka Complex B – Wing Tembhode Road, Palghar, Maharashtra, India – 401404.
As per the financials filed for FY 2024, the company reported a revenue of ₹32.57 Lakh, a growth of 11% compared to the previous year. For the same year it recorded a net profit of ₹2.24 Lakh (net margin 6.9%) and EBITDA of ₹2.79 Lakh (EBITDA margin 8.6%). Revenue has grown at a compounded annual rate (CAGR) of 8% over three years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Mardia Formulation (India) Private Limited's registered office is in Palghar, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressBl. No. 207 Renuka Complex B – Wing Tembhode Road, Palghar, Maharashtra, India – 401404
- IndustryChemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals
To see the full contact details of Mardia Formulation (India) Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Mardia Formulation (India) is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations |
To see the full business activity and turnover split of Mardia Formulation (India) Private Limited, buy the company report.
Financials of Mardia Formulation (India) Private Limited
FY 2025 filings availableMardia Formulation (India) Private Limited reported revenue of ₹32.57 Lakh (up 11% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 8% over three years, including 11% growth in the latest year. EBITDA rose 260% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹2.79 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹2.24 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 8.6% | ||||
| Net Profit Margin | 6.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Mardia Formulation (India) Private Limited, buy the company report.
Board of directors of Mardia Formulation (India) Private Limited
Mardia Formulation (India) has 3 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Gayan Prakash Mardia | Director | 14 Jul 1999 | 27 Years 3 Months | Current |
| Anand Mardia | Director | 14 Jul 1999 | 27 Years 3 Months | Current |
| Susheela Mardia | Director | 02 Apr 2018 | 8 Years 6 Months | Current |
Peer comparison
Mardia Formulation (India) Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Etheric Remedies Private Limited | ₹33.37 Lakh (FY 2024) | 427.0% | Delhi, India | |||
| Drati Pharmaceuticals Private Limited | ₹33.29 Lakh (FY 2024) | -10.0% | Thane, Maharashtra, India | |||
| Reskon Pharmaceutical Private Limited | ₹33.22 Lakh (FY 2024) | 71.0% | Thane, Maharashtra, India | |||
| Vetrich Animal Health Care Private Limited | ₹33.22 Lakh (FY 2025) | 6.0% | Pune, Maharashtra, India | |||
| Ashtakarma Healthcare (OPC) Private Limited | ₹32.92 Lakh (FY 2025) | 41.0% | Thane, Maharashtra, India | |||
| Mardia Formulation (India) Private Limitedthis company | ₹32.57 Lakh (FY 2024) | ₹2.24 Lakh | 6.9% | 11.0% | Palghar, Maharashtra, India | |
| Upraj Pharmaceuticals Private Limited | ₹32.38 Lakh (FY 2025) | 39.0% | Jaipur, Rajasthan, India | |||
| Elvimed Pharma Private Limited | ₹32.25 Lakh (FY 2023) | Pune, Maharashtra, India | ||||
| Aurenyx Pharmatech Private Limited | ₹31.57 Lakh (FY 2025) | 29.0% | Shirur, Maharashtra, India | |||
| Aerolite Pharmaceuticals Private Limited | ₹31.53 Lakh (FY 2025) | 17.0% | Pune, Maharashtra, India | |||
| Clinimed Allergy Solutions Private Limited | ₹31.5 Lakh (FY 2024) | 343.0% | Bangalore, Karnataka, India |
To see the full peer comparison of Mardia Formulation (India) Private Limited, buy the company report.
Auditor
Mardia Formulation (India) Private Limited is audited by R LASOD & CO for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| R LASOD & CO | FY 2017 | 008697C |
Shareholding
The shareholding of Mardia Formulation (India) Private Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 | FY 2016 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Mardia Formulation (India) Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Mardia Formulation (India) Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Mardia Formulation (India) Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Mardia Formulation (India) has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCM9536D1ZG | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Mardia Formulation (India) Private Limited, buy the company report.
Recent activity
Mardia Formulation (India) Private Limited has 4 board changes on record since 1999: 3 appointments and 1 cessation. The latest: Susheela Mardia ceased to be Additional Director on 30 Sep 2018.
Frequently asked questions
Mardia Formulation (India) is an active private limited company based in Palghar, Maharashtra, India. The company works in chemical products, within the chemicals industry. It was incorporated on 14 July 1999 (27+ years old) and is registered under CIN U24230MH1999PTC120797.
Mardia Formulation (India) has 3 current directors:
- Gayan Prakash Mardia - Director
- Anand Mardia - Director
- Susheela Mardia - Director
The latest financial statements of Mardia Formulation (India) on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Mardia Formulation (India) is 27AABCM9536D1ZG, registered in Maharashtra.
The CIN (Corporate Identification Number) of Mardia Formulation (India) is U24230MH1999PTC120797. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Mardia Formulation (India) was incorporated on 14 July 1999, making it 27+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Mardia Formulation (India) by revenue are Etheric Remedies Private Limited, Drati Pharmaceuticals Private Limited, Reskon Pharmaceutical Private Limited, Vetrich Animal Health Care Private Limited, Ashtakarma Healthcare (OPC) Private Limited and 5 more, all in the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).
Susheela Mardia ceased to be Additional Director on 30 Sep 2018. Susheela Mardia was appointed as Director on 02 Apr 2018. Anand Mardia was appointed as Director on 14 Jul 1999. Mardia Formulation (India) has 4 board changes on record in total.
The registered office of Mardia Formulation (India) is at Bl. No. 207 Renuka Complex B – Wing Tembhode Road, Palghar, Maharashtra, India – 401404.
Mardia Formulation (India) operates in the chemicals industry, in the chemical products segment.
The compliance status of Mardia Formulation (India) is compliant as of 29 August 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
